

# Appendix E: Sample Abstraction Forms

**Project Title** Comparison of Therapies for Clinically Localized Prostate Cancer

**Research question:** How do provider/hospital characteristics affect outcomes overall and differentially (e.g. geographic region and volume)?

**Abstraction Form (complete for each article)**

Study ID (PUBMED) \_\_\_\_\_

Title: \_\_\_\_\_

Authors: \_\_\_\_\_

Reference: \_\_\_\_\_

Description of Database: \_\_\_\_\_

Abstractor: \_\_\_\_\_

**VERIFICATION/SELECTION OF STUDY ELIGIBILITY**

Language of the publication			
English	Yes	No	
Target population			
Patients with prostate adenocarcinoma	Yes	No	Combined
Stage of cancer			
I-II	Yes	No	Combined
Treatments			
Radical prostatectomy	Yes	No	
Radiation therapy	Yes	No	
Interstitial brachytherapy	Yes	No	
Cryosurgery	Yes	No	
Expectant management	Yes	No	
Hormonal therapy as primary therapy	Yes	No	
Provider characteristics			
Hospital volume	Yes	No	
Surgeon volume	Yes	No	
Hospital status	Yes	No	
Physician specialty	Yes	No	
Provider location	Yes	No	
Clinical outcomes			
Mortality	Yes	No	
Morbidity	Yes	No	
Urinary complications	Yes	No	
Long term incontinence	Yes	No	
Operational quality indicators	Yes	No	
Positive margins	Yes	No	
Length of stay	Yes	No	

**Publication type (mark one)**

- Published article
- Administrative report
- Dissertation
- Abstract/Presentation
- Book/book chapter

Purpose/aim of study \_\_\_\_\_

**Design of the study (mark one)**

- prospective cohort
- retrospective cohort
- cross-sectional
- descriptive study
- case-control
- case-series
- randomized controlled clinical trial
- not randomized clinical interventions
- ecologic

**ASSESSMENT OF STUDY QUALITY**

Score each domain on a scale of 0 (poor, not defined) to 5 (excellent, clearly defined)

1. Study question clearly focused and appropriate
2. The objectives and primary hypothesis of the study clearly stated
3. Description of the target population
4. Description and clear definition of the exposure
5. Description and clear definition of primary and secondary outcomes
6. Validation of the measurements of the exposure
7. Validation of the measurements of the outcomes
8. The process of the subjects' selection
9. The adequacy of the sampling (random selection or not)
10. The assessment of selection bias
11. Was the sample size justified
12. Censoring (when applicable)
13. Loss of followup
14. Length of followup (when applicable)
15. Assessment of possible confounding factors:
16. Validity of the measurements
17. Matching
18. Adjustment
19. Standardization
20. Measurement of possible effect measure modification
21. Reporting of the statistical analysis
22. Precision of the reported estimates of the association between exposure and outcomes (95% CI; maximum likelihood test, p value, the ratio of the highest 95% CI to the lowest)
23. Comparison of crude and adjusted estimates
24. Justification of the used models statistical models
25. Assessment of nonlinear associations
26. Appropriate multivariate-techniques to adjust for confounding factors (multivariate regression, propensity scores)
27. Subgroups analysis - Single site vs. multi center study
28. Limitations of the study
29. The major results of the study
30. The appropriate conclusions of the study
31. External validity of the study

**Level of evidence of the individual study (mark one)**

Interventions:

- I – Well-designed randomized controlled trial
- II-1A - Well-designed controlled trial with pseudo-randomization
- II-1B - Well-designed controlled trial without randomization

Observational studies

- I-2A - Well-designed cohort (prospective) study with concurrent controls
- II-2B - Well-designed cohort (prospective) study with historical controls
- II-2C - Well-designed cohort (retrospective) study with concurrent controls
- II-3 – Well-designed case-controlled (retrospective) study
- III – Large differences from comparisons between times and/or places
- Y – Opinion of respected authorities based in clinical experience

**Source of sampling and data collection** (define) \_\_\_\_\_

**Country where the study was conducted** \_\_\_\_\_

**Financial Support:** Industry, National Grant or foundations, other, define \_\_\_\_\_

**Time interval outcomes occurred** \_\_\_\_\_

**Data to collect outcomes information:** Administrative database, define \_\_\_\_\_  
Medical Records \_\_\_\_\_

**Adjustment for patient characteristics:**

Patient age	Yes	No
Patient Race	Yes	No
Cancer stage	Yes	No
Patient Socio-economic Status	Yes	No
Patient Co morbidity	Yes	No

**Hospital Affiliation with Medical School** Yes NO

**Patient Demographics**

Number of patients (n, N, %): \_\_\_\_\_

Age (years, %): \_\_\_\_\_ Mean: \_\_\_\_\_ Min: \_\_\_\_\_ Max: \_\_\_\_\_ ±SD: \_\_\_\_\_ ±SE: \_\_\_\_\_

Race (n, %) White: \_\_\_\_\_ African-American: \_\_\_\_\_

Other: \_\_\_\_\_ Describe: \_\_\_\_\_

Tumor characteristics, Describe \_\_\_\_\_

**Comments:** \_\_\_\_\_

\_\_\_\_\_  
\_\_\_\_\_

Patient Inclusion Criteria: \_\_\_\_\_

Patient Exclusion Criteria: \_\_\_\_\_

Surgeon Inclusion Criteria: \_\_\_\_\_

Surgeon Exclusion Criteria: \_\_\_\_\_

**Group/Sub-Group Definitions**

Group ID	Patients (n)	Define

**Physician specialty:** Urologist Radiation oncologist, General Internist, Other, define \_\_\_\_\_

**Provider Location:** State, Region, County, Other, define \_\_\_\_\_

**Type of Volume**

**Hospital Volume**

1. Number of patients: \_\_\_\_\_
2. Number of hospitals: \_\_\_\_\_  
(e.g., low, medium, high)
3. Description: \_\_\_\_\_
4. Annual Volume, Define: \_\_\_\_\_
5. Mean: \_\_\_\_\_

1. Number of patients: \_\_\_\_\_
2. Number of hospitals: \_\_\_\_\_  
(e.g., low, medium, high)
3. Description: \_\_\_\_\_
4. Annual Volume, Define: \_\_\_\_\_
5. Mean: \_\_\_\_\_

**Comments:** \_\_\_\_\_

\_\_\_\_\_

Number of patients: \_\_\_\_\_

1. Number of hospitals: \_\_\_\_\_  
(e.g., low, medium, high)
2. Description: \_\_\_\_\_
3. Annual Volume, Define: \_\_\_\_\_
4. Mean: \_\_\_\_\_

**Comments:**

---

---

**Surgeon Volume**

1. Number of patients: \_\_\_\_\_  
(e.g., low, medium, high)
2. Description: \_\_\_\_\_
3. Annual Volume, Define: \_\_\_\_\_
4. Mean: \_\_\_\_\_
5. Median: \_\_\_\_\_

1. Number of patients: \_\_\_\_\_  
(e.g., low, medium, high)
  2. Description: \_\_\_\_\_
  3. Annual Volume, Define: \_\_\_\_\_
  4. Mean: \_\_\_\_\_
- Median: \_\_\_\_\_

1. Number of patients: \_\_\_\_\_  
(e.g., low, medium, high)
2. Description: \_\_\_\_\_
3. Annual Volume, Define: \_\_\_\_\_
4. Mean: \_\_\_\_\_
5. Median: \_\_\_\_\_

**Treatment utilization**

**Outcomes**

Treatment	Rate/ 100,000 males	% of Treated/ diagnosed	Relative risk of treatment utilization	Cost \$	Length of stay, Days
Radical prostatectomy					
Radiation therapy					
Interstitial brachytherapy					
Cryosurgery					
Expectant management					
Hormonal therapy as primary therapy					

**Comments:** \_\_\_\_\_  
\_\_\_\_\_

**Prostate Cancer screening, Incidence, and mortality**

Provider characteristics	PSA testing, %	Incidence total/100,000	Incidence, localized PC/100,000	Mortality total/ 100,000	Mortality, cancer specific/ 100,000
Physician specialty					
Number of urologists					
Number of radiation oncologists					
Provider location					

**Clinical outcomes in patients with prostate cancer treated with radical prostatectomy**

Clinical outcomes	Events Rate Standard Deviation	Relative Risk, 95% CI
Surgery related mortality		
Morbidity		
Urinary complications		
Long-term incontinence		
Operational quality indicators		
Positive margins		
Blood loss		
Adjuvant therapy		
Length of stay		
Readmission		

**Comments:** \_\_\_\_\_  
\_\_\_\_\_